Table 1.

Pre-clinical animal studies of anti-miRNA oligonucleotide (AMO) based therapeutics in diabetes and related metabolic conditions

MicroRNA	Metabolic phenotype/disease	References
let-7	Type 2 diabetes	Frost and Olson, PNAS [15]
miR-34	Obesity/type 2 diabetes	Fu et al., PNAS [16] Choi et al., Aging Cell [17]
miR-103/107	Obesity/type 2 diabetes	Trajkovski et al., Nature [18••]
miR-802	Obesity/type 2 diabetes	Kornfeld et al., Nature [19]
miR-208a	Obesity/type 2 diabetes	Grueter et al., Cell [20]
miR-181a	Insulin resistance/type 2 diabetes	Zhou et al., Diabetologia [21]
miR-379	Obesity/hyperlipidemia	deGuia et al., EMBO Journal [22]
miR-146b	Obesity	Ahn et al., EMBO Molecular Medicine [23]
miR-24	Steatosis/hyperlipidemia	Ng et al., Hepatology [24]
miR-29	Hyperlipidemia	Kurtz et al., Scientific Reports [25]